Page last updated: 2024-10-18

dihydroxyphenylalanine and Bilateral Headache

dihydroxyphenylalanine has been researched along with Bilateral Headache in 4 studies

Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19903 (75.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
de Matos Balsalobre, N1
Dos Santos, E1
Mariano Dos Santos, S1
Arena, AC1
Konkiewitz, EC1
Ziff, EB1
Nazari Formagio, AS1
Leite Kassuya, CA1
HODGE, JV1
NYE, ER1
EMERSON, GW1
Schwab, RS1
Poskanzer, DC1
England, AC1
Young, RR1
Tamarkin, NR1
Goodwin, FK1
Axelrod, J1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551]Phase 3223 participants (Actual)Interventional2014-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Movement Disorder's Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (Parts I-III Combined Scores)

"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).

,,,
Interventionunits on a scale (Mean)
BaselineChange from Baseline at Week 8Change from Baseline at Week 16Change from Baseline at Week 28Change from Baseline at Week 40Change from Baseline at Week 52Change from Baseline at Week 64Change from Baseline at Week 76Change from Baseline at Week 88Change from Baseline at Week 100
ADS-5102 1A41.81.21.64.87.513.28.811.711.311.4
ADS-5102 Group 1P45.6-2.8-1.41.5-0.42.62.67.33.73.7
ADS-5102 Group 252.80.85.76.51.66.16.19.46.46.5
ADS-5102 Group 352.4-5.3-5.2-5.3-4.8-4.6-4.6-4.90.94.1

Change From Baseline in Movement Disorder's Society - Unified Parkinson's Disease Rating Scale MDS-UPDRS (Part IV - Motor Complications)

"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).

,,,
Interventionunits on a scale (Mean)
BaselineChange in Baseline from Week 8Change in Baseline from Week 16Change from Baseline at Week 28Change from Baseline at Week 40Change from Baseline at Week 52Change from Baseline at Week 64Change from Baseline at Week 76Change from Baseline at Week 88Change from Baseline at Week 100
Group 1a6.5-0.2-0.8-0.30.00.20.40.90.40.4
Group 1P9.6-3.4-3.2-3.3-2.8-2.9-3.3-2.9-2.8-2.4
Group 29.8-3.6-1.1-1.4-2.9-2.5-1.9-2.7-3.7-3.6
Group 310.4-4.0-3.9-4.4-4.7-3.6-2.5-3.7-4.3-3.6

Number of Participants With Reported AEs and Safety-Related Study Drug Discontinuations

The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks

,,,
InterventionParticipants (Count of Participants)
AEStudy drug-related AESAEsPermanent discontinuation due to AEPermanent discontinuation due to drug-related AEMild AEsModerate AEsMild drug-related AEModerate drug-related AESevere drug-related AE
Group 1a573116124122516123
Group 1P7045212115133615237
Group 223166643133121
Group 355321710811265225

Other Studies

4 other studies available for dihydroxyphenylalanine and Bilateral Headache

ArticleYear
Potential anti-arthritic and analgesic properties of essential oil and viridiflorol obtained from Allophylus edulis leaves in mice.
    Journal of ethnopharmacology, 2023, Jan-30, Volume: 301

    Topics: Analgesics; Animals; Anti-Inflammatory Agents; Carrageenan; Dexamethasone; Dihydroxyphenylalanine; D

2023
MONOAMINE-OXIDASE INHIBITORS, BROAD BEANS, AND HYPERTENSION.
    Lancet (London, England), 1964, May-16, Volume: 1, Issue:7342

    Topics: Dihydroxyphenylalanine; Fabaceae; Headache; Hypertension; Monoamine Oxidase Inhibitors; Oxidoreducta

1964
Amantadine in Parkinson's disease. Review of more than two years' experience.
    JAMA, 1972, Nov-13, Volume: 222, Issue:7

    Topics: Aged; Amantadine; Ataxia; Constipation; Depression; Diarrhea; Dihydroxyphenylalanine; Drug Synergism

1972
Rapid elevation of biogenic amine metabolites in human CSF following probenecid.
    Life sciences. Pt. 1: Physiology and pharmacology, 1970, Dec-15, Volume: 9, Issue:24

    Topics: Administration, Oral; Affective Symptoms; Dihydroxyphenylalanine; Female; Headache; Humans; Hydroxyi

1970